Previous close | 0.7912 |
Open | 0.7800 |
Bid | 0.7933 x 100 |
Ask | 0.7979 x 300 |
Day's range | 0.7725 - 0.8179 |
52-week range | 0.6300 - 1.3700 |
Volume | |
Avg. volume | 1,483,108 |
Market cap | 327.175M |
Beta (5Y monthly) | 1.96 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.1300 |
Earnings date | 01 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 1.00 |
Denali Therapeutics (DNLI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Key Insights Using the 2 Stage Free Cash Flow to Equity, Amarin fair value estimate is US$1.01 Amarin is estimated to...
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD)1 -- -- Approval marks eighth national reimbursement of VAZKEPA® in Europe -- DUBLIN, Ireland and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announces that the Portuguese Ministry of Health has approved VAZKEPA® (icosapent ethyl) for national re